Zydus Lifesciences is advancing a novel formulation of semaglutide aimed at addressing diabetes and obesity, two chronic conditions that are rapidly increasing in prevalence and severity across the globe.
User-Friendly One-Pen System Simplifies Treatment
In a significant innovation, Zydus has developed a single-pen delivery system that allows users to select from multiple dose strengths within the same device. This eliminates the need for multiple injection tools, making treatment more convenient and accessible for patients.
Strategic Launch Planned for India and Beyond
“Our current strategy for semaglutide, both for India and developing markets, focuses on commercialising this novel formulation,” said Sharvil Patel, Managing Director of Zydus, during a recent earnings call. He confirmed that the company is on track for a day-one launch in India. The goal is to capture the initial market wave upon regulatory approval.
Global Expansion and Licensing Opportunities Underway
As reported by indiapharmaoutlook, Zydus also plans to extend the product’s reach into other emerging markets. Patel noted growing interest from global companies seeking co-marketing partnerships, as Zydus explores licensing opportunities to expand access.
Patented Device Technology Supports Innovation
While the semaglutide formulation was developed in-house, the device technology was sourced from a partner and is already patented. This collaboration enables Zydus to offer a cutting-edge delivery system that could improve medication adherence and outcomes for millions living with metabolic disorders.
Zydus Lifesciences continues to strengthen its position in the chronic disease management space. It combines scientific innovation with a global strategy to improve access and ease of treatment.